Migraine Diagnosis and Treatment: Results From the An

Headache 41, 638-645 DOI: 10.1046/j.1526-4610.2001.041007638.x

Citation Report

CITATION	

#	Article	IF	CITATIONS
1	EPIDEMIOLOGY AND IMPACT OF PRIMARY HEADACHE DISORDERS. Medical Clinics of North America, 2001, 85, 887-895.	1.1	41
3	Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II. Headache, 2001, 41, 646-657.	1.8	1,933
4	Pitfalls in migraine diagnosis and management. Clinical Cornerstone, 2001, 4, 26-35.	1.0	10
5	Acute and prophylactic management of migraine. Clinical Cornerstone, 2001, 4, 36-52.	1.0	24
6	New Guidelines for the Management of Migraine in Primary Care. Current Medical Research and Opinion, 2002, 18, 414-439.	0.9	90
7	Migraine in the United States. Neurology, 2002, 58, 885-894.	1.5	542
8	Key factors in the primary care diagnosis of migraine. Expert Review of Neurotherapeutics, 2002, 2, 305-310.	1.4	0
10	How to treat a migraine. Nursing, 2002, 32, 76-77.	0.2	1
11	Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache. Annals of Internal Medicine, 2002, 137, 840.	2.0	171
12	Migraine — Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	13.9	1,692
13	Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opinion on Pharmacotherapy, 2002, 3, 237-248.	0.9	6
15	Behavioral treatment strategies for migraine and tension-type headache: a review of the evidence and future directions. Expert Review of Neurotherapeutics, 2002, 2, 749-760.	1.4	4
16	The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers. Clinical Therapeutics, 2002, 24, 1887-1901.	1.1	7
17	Do Butalbital-Containing Products Have a Role in the Management of Migraine?. Pharmacotherapy, 2002, 22, 1029-1035.	1.2	31
18	Do Over-the-counter medications for migraine hinder the physician?. Current Pain and Headache Reports, 2002, 6, 162-167.	1.3	8
19	Migraine, Midrin, and Imitrex. Headache, 2002, 42, 322-323.	1.8	2
20	Migraine Management: Contrasting Patient Preferences With Current Clinical End Points: Introduction. Headache, 2002, 42, 1-2.	1.8	3
21	What Do Patients With Migraine Want From Acute Migraine Treatment?. Headache, 2002, 42, 3-9.	1.8	214

#	Article	IF	CITATIONS
22	What is the Evolutionary Advantage of Migraine?. Cephalalgia, 2002, 22, 624-632.	1.8	54
23	Behavioral management of recurrent headache: three decades of experience and empiricism. Applied Psychophysiology Biofeedback, 2002, 27, 163-181.	1.0	146
24	Applications of computerized adaptive testing (CAT) to the assessment of headache impact. Quality of Life Research, 2003, 12, 935-952.	1.5	150
25	Acute treatment of migraine headache. Current Treatment Options in Neurology, 2003, 5, 423-430.	0.7	11
26	Chronic daily headache. Current Treatment Options in Neurology, 2003, 5, 467-479.	0.7	7
27	Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. Journal of Headache and Pain, 2003, 4, 146-151.	2.5	56
28	The global burden of migraine. Journal of Headache and Pain, 2003, 4, s3-s11.	2.5	16
29	Over-the-Counter Drugs for Acute Migraine Attacks: Literature Review and Recommendations. Pharmacotherapy, 2003, 23, 494-505.	1.2	49
30	Cost savings in migraine associated with less chest pain on new triptan therapy Headache, 2003, 43, 302-302.	1.8	0
31	Medical Oophorectomy With and Without Estrogen Add-Back Therapy in the Prevention of Migraine Headache. Headache, 2003, 43, 309-321.	1.8	83
32	Health Care Utilization in Patients With Migraine: Demographics and Patterns of Care in the Ambulatory Setting. Headache, 2003, 43, 330-335.	1.8	72
33	Rapid and Sensitive Paradigm for Screening Patients With Headache in Primary Care Settings. Headache, 2003, 43, 441-450.	1.8	47
34	Impact of a Group-Based Model of Disease Management for Headache. Headache, 2003, 43, 621-627.	1.8	38
35	Differences in Anger Expression Between Individuals With and Without Headache After Controlling for Depression and Anxiety. Headache, 2003, 43, 651-663.	1.8	55
36	Botulinum Toxin Type A as an Effective Prophylactic Treatment in Primary Headache Disorders. Headache, 2003, 43, 853-860.	1.8	83
37	Pseudosinus Headaches: Misdiagnosis of Migraine by Migraineurs and Physicians. Headache, 2003, 43, 1010-1012.	1.8	1
38	Epidemiological and Clinical Characteristics of Migraine and Tension Type Headache in 1146 Females in Kayseri, Turkey. Cephalalgia, 2003, 23, 381-388.	1.8	57
39	Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstetrics and Gynecology, 2003, 102, 835-842.	1.2	63

	CITATION	Report	
#	Article	IF	CITATIONS
40	A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clinical Therapeutics, 2003, 25, 331-341.	1.1	14
41	Migraine treatment patterns and patient satisfaction with prior therapy: A substudy of a multicenter trial of rizatriptan effectiveness. Clinical Therapeutics, 2003, 25, 2053-2069.	1.1	19
42	Cómo tratar la migraña. Nursing (Ed Española), 2003, 21, 50-51.	0.0	0
43	Assessing disability using the migraine disability assessment questionnaire. Expert Review of Neurotherapeutics, 2003, 3, 317-325.	1.4	7
44	Analgesic use: A predictor of chronic pain and medication overuse headache. Neurology, 2003, 61, 160-164.	1.5	217
45	Comorbidity of migraine and depression. Neurology, 2003, 60, 1308-1312.	1.5	564
46	Headache Assessment and Management. JAMA - Journal of the American Medical Association, 2003, 289, 1430.	3.8	40
47	Estimating the cost of an emergency room visit for migraine headache. Journal of Medical Economics, 2003, 6, 43-53.	1.0	10
48	A self-administered screener for migraine in primary care. Neurology, 2003, 61, 375-382.	1.5	495
49	Lost Productive Time and Cost Due to Common Pain Conditions in the US Workforce. JAMA - Journal of the American Medical Association, 2003, 290, 2443.	3.8	1,264
50	Pain-Free Efficacy After Treatment With Sumatriptan in the Mild Pain Phase of Menstrually Associated Migraine. Obstetrics and Gynecology, 2003, 102, 835-842.	1.2	38
51	Migraine: an ophthalmologist's perspective. Current Opinion in Ophthalmology, 2003, 14, 344-352.	1.3	12
52	Patterns of health care utilization for migraine in England and in the United States. Neurology, 2003, 60, 441-448.	1.5	159
53	Pharmacist-managed headache clinic. American Journal of Health-System Pharmacy, 2004, 61, 2548-2550.	0.5	7
54	Pharmacologic Management of Migraine. Annals of Internal Medicine, 2004, 140, W-26.	2.0	0
55	Adrenal Insufficiency from Inhaled Corticosteroids. Annals of Internal Medicine, 2004, 140, W-27.	2.0	10
56	Randomized Trial of Warfarin Nomograms. Annals of Internal Medicine, 2004, 140, 488.	2.0	2
57	Prevention of Ventilator-Associated Pneumonia. Annals of Internal Medicine, 2004, 140, 486.	2.0	3

#	Article	IF	CITATIONS
58	Prevalence of Migraine in Patients With a History of Self-reported or Physician-Diagnosed "Sinus" Headache. Archives of Internal Medicine, 2004, 164, 1769.	4.3	213
59	Increased frequency of migraine among women with endometriosis. Human Reproduction, 2004, 19, 2927-2932.	0.4	62
60	Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey – phase IV*. Current Medical Research and Opinion, 2004, 20, 1777-1783.	0.9	11
61	Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology, 2004, 62, 1540-1544.	1.5	132
62	Depression and comorbidity in community-based patients with epilepsy or asthma. Neurology, 2004, 63, 1008-1014.	1.5	274
63	Prevalence and impact of migraine and probable migraine in a health plan. Neurology, 2004, 63, 1432-1438.	1.5	133
64	What role do community pharmacists currently play in the management of headache? A hospital-based perspective. International Journal of Clinical Practice, 2004, 58, 257-259.	0.8	10
65	Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. International Journal of Clinical Practice, 2004, 58, 695-705.	0.8	29
66	Migraine and chronic daily headache management: a qualitative study of patients' perceptions. Scandinavian Journal of Caring Sciences, 2004, 18, 294-303.	1.0	43
67	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424.	1.8	108
67 68		1.8 1.8	108 99
	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs — a Nation-wide Population-based		
68	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs — a Nation-wide Population-based Survey in Sweden. Cephalalgia, 2004, 24, 455-465.	1.8	99
68 69	 Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs â€" a Nation-wide Population-based Survey in Sweden. Cephalalgia, 2004, 24, 455-465. The Aura: A Tertiary Care Study of 952 Migraine Patients. Cephalalgia, 2004, 24, 728-734. 	1.8 1.8	99 82
68 69 70	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs — a Nation-wide Population-based Survey in Sweden. Cephalalgia, 2004, 24, 455-465. The Aura: A Tertiary Care Study of 952 Migraine Patients. Cephalalgia, 2004, 24, 728-734. What Do Patients Want from Acute Migraine Treatment?. Cephalalgia, 2004, 24, 8-15.	1.8 1.8 1.8	99 82 189
68 69 70 71	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs â€" a Nation-wide Population-based Survey in Sweden. Cephalalgia, 2004, 24, 455-465. The Aura: A Tertiary Care Study of 952 Migraine Patients. Cephalalgia, 2004, 24, 728-734. What Do Patients Want from Acute Migraine Treatment?. Cephalalgia, 2004, 24, 8-15. Clinical Benefits of Early Triptan Therapy for Migraine. Cephalalgia, 2004, 24, 24-30. The medical care utilization and costs associated with migraine headache. Journal of General Internal	1.8 1.8 1.8 1.8	99 82 189 210
 68 69 70 71 72 	Triptans and CNS Side-Effects. Cephalalgia, 2004, 24, 417-424. Attitudes and Burden of disease among Self-Considered Migraineurs — a Nation-wide Population-based Survey in Sweden. Cephalalgia, 2004, 24, 455-465. The Aura: A Tertiary Care Study of 952 Migraine Patients. Cephalalgia, 2004, 24, 728-734. What Do Patients Want from Acute Migraine Treatment?. Cephalalgia, 2004, 24, 8-15. Clinical Benefits of Early Triptan Therapy for Migraine. Cephalalgia, 2004, 24, 24-30. The medical care utilization and costs associated with migraine headache. Journal of General Internal Medicine, 2004, 19, 1005-1012. Lifetime Prevalence of Migraine and Other Headaches Lasting 4 or More Hours: The Atherosclerosis	1.8 1.8 1.8 1.8 1.3	 99 82 189 210 58

#	Article	IF	CITATIONS
76	Simple and Efficient Recognition of Migraine With 3-Question Headache Screen. Headache, 2004, 44, 323-327.	1.8	36
77	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Headache, 2004, 44, 414-425.	1.8	327
78	Tools for Diagnosing Migraine and Measuring Its Severity. Headache, 2004, 44, 387-398.	1.8	43
79	Introduction: Cardiovascular Safety and Triptans in the Acute Treatment of Migraine. Headache, 2004, 44, S1-S4.	1.8	6
80	Cardiovascular Tolerability and Safety of Triptans: A Review of Clinical Data. Headache, 2004, 44, S20-S30.	1.8	104
81	Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurology, 2004, 4, 4.	0.8	25
82	Migraine Headache Misconceptions: Barriers to Effective Care. Pharmacotherapy, 2004, 24, 638-648.	1.2	19
83	ID-migraine. Neurological Sciences, 2004, 25, s258-s260.	0.9	19
84	Treatment preferences and the selection of acute migraine medications: results from a population-based survey. Journal of Headache and Pain, 2004, 5, 123-130.	2.5	14
85	Economic evidence in migraine and other headaches: a review. European Journal of Health Economics, 2004, 5, s43-s54.	1.4	42
86	The epidemiology and impact of migraine. Current Neurology and Neuroscience Reports, 2004, 4, 98-104.	2.0	87
87	The changing face of migraine. Current Pain and Headache Reports, 2004, 8, 85-90.	1.3	1
88	Anticonvulsants in migraine. Current Pain and Headache Reports, 2004, 8, 244-250.	1.3	12
89	The Migraine Disability Assessment (MIDAS) Questionnaire in the Primary-Care Setting. Pharmaceutical Medicine, 2004, 18, 325-335.	0.4	0
90	Economic Impact of Migraine and Other Episodic Headaches in France. Pharmacoeconomics, 2004, 22, 985-999.	1.7	81
91	Impact of migraine on patients and their families: the Migraine And Zolmitriptan Evaluation (MAZE) survey – Phase III. Current Medical Research and Opinion, 2004, 20, 1143-1150.	0.9	88
92	Burden of headache. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 353-359.	0.7	20
93	Diagnosis and classification of headache. Primary Care - Clinics in Office Practice, 2004, 31, 243-259.	0.7	9

		TATION REPORT	
#	Article	IF	CITATIONS
94	Migraine diagnosis and treatment. Primary Care - Clinics in Office Practice, 2004, 31, 277-292.	0.7	2
96	Epidemiology and impact of headache: an overview. Primary Care - Clinics in Office Practice, 2004, 31 237-241.	, 0.7	10
97	Common headache misdiagnoses. Primary Care - Clinics in Office Practice, 2004, 31, 395-405.	0.7	10
98	Challenging or difficult headache patients. Primary Care - Clinics in Office Practice, 2004, 31, 429-440). 0.7	6
99	Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity. Journal of Clinical Epidemiology, 2004, 57, 962-972.	2.4	48
100	The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. Journal of Clinical Epidemiology, 2004, 57, 1271-1278.	2.4	121
101	Migraine. Lancet, The, 2004, 363, 381-391.	6.3	372
103	Prevention of Ventilator-Associated Pneumonia. Annals of Internal Medicine, 2004, 140, 486.	2.0	2
104	Migraine practice patterns among neurologists. Neurology, 2004, 62, 1926-1931.	1.5	50
105	Viral or Acute Bacterial Rhinosinusitis?. Nurse Practitioner, 2005, 30, 30-41.	0.2	0
106	Identifying migraine in primary care settings. The American Journal of Medicine: Supplement, 2005, 12 11-17.	18, 1.7	5
107	Headache as a side effect of combination estrogen-progestin oral contraceptives: A systematic review American Journal of Obstetrics and Gynecology, 2005, 193, 636-649.	J. 0.7	81
108	The Fixed Combination of Acetylsalicylic acid, Paracetamol and Caffeine is more Effective than Single Substances and Dual Combination for the Treatment of Headache: a Multicentre, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Parallel Group Study. Cephalalgia, 2005, 25, 776-787.	1.8	193
109	The Predictive Value of Abbreviated Migraine Diagnostic Criteria. Headache, 2005, 45, 1102-1112.	1.8	27
110	A Self-Administered Behavioral Intervention Using Tailored Messages for Migraine. Headache, 2005, 4 1124-1139.	5, 1.8	38
111	Valdecoxib for Treatment of a Single, Acute, Moderate to Severe Migraine Headache. Headache, 2005 45, 1151-1162.	5, 1.8	22
112	Patterns and Predictors of Prescription Medication Use in the Management of Headache: Findings From the 2000 Medical Expenditure Panel Survey. Headache, 2005, 45, 1171-1180.	1.8	23
113	Tramadol/Acetaminophen for the Treatment of Acute Migraine Pain: Findings of a Randomized, Placeboâ€Controlled Trial. Headache, 2005, 45, 1317-1327.	1.8	38

		Report	
#	ARTICLE	IF	CITATIONS
114	Development and Validation of the Migraine Screen Questionnaire (MSâ \in Q). Headache, 2005, 45, 1328-1338.	1.8	66
115	Migraine Therapy: A Survey of Pharmacists' Knowledge, Attitudes, and Practice Patterns. Headache, 2005, 45, 47-52.	1.8	27
116	Epidemiology of Migraine in Latin America: An Editorial. Headache, 2005, 45, 103-104.	1.8	13
117	Prevalence of Migraine in Latin America. Headache, 2005, 45, 106-117.	1.8	76
118	Clinical Characteristics and Patterns of Medication Use of Migraneurs in Latin America From 12 Cities in 6 Countries. Headache, 2005, 45, 118-126.	1.8	46
119	Headache and Combination Estrogenâ€Progestin Oral Contraceptives: Integrating Evidence, Guidelines, and Clinical Practice. Headache, 2005, 45, 224-231.	1.8	43
120	Aspirin Is Efficacious for the Treatment of Acute Migraine. Headache, 2005, 45, 283-292.	1.8	80
121	Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Doubleâ€Blind, Placeboâ€Controlled Study. Headache, 2005, 45, 315-324.	1.8	215
122	Thunderclap Headache and Spontaneous Intracranial Hypotension. Headache, 2005, 45, 392-393.	1.8	9
123	Response to Letter by Famularo et al. Headache, 2005, 45, 393-393.	1.8	0
124	Childhood Exposure to Secondâ€Hand Tobacco Smoke and the Development of Cluster Headache. Headache, 2005, 45, 393-394.	1.8	19
125	Outpatient Continuous Intravenous Dihydroergotamine for Refractory Headache. Headache, 2005, 45, 394-395.	1.8	1
126	The Wrong War. Headache, 2005, 45, 395-396.	1.8	0
127	Migraine Treated with Acyclovir. Headache, 2005, 45, 396-397.	1.8	4
128	Depressive Symptoms and Insecure Attachment as Predictors of Disability in a Clinical Population of Patients With Episodic and Chronic Migraine. Headache, 2005, 45, 561-570.	1.8	57
129	Patients' Management of Migraine and Chronic Daily Headache: A Study of the Members of the Migraine Action Association (United Kingdom). Headache, 2005, 45, 571-581.	1.8	14
130	The Quality of Headache Treatment in The United States: Review and Analysis of Recent Data. Headache, 2005, 45, 939-946.	1.8	6
131	Acetaminophen, Aspirin, and Caffeine Versus Sumatriptan Succinate in the Early Treatment of Migraine: Results From the ASSET trial. Headache, 2005, 45, 973-982.	1.8	81

#	ARTICLE	IF	CITATIONS
132	Topiramate Improves Health-Related Quality of Life When Used to Prevent Migraine. Headache, 2005, 45, 1023-1030.	1.8	57
133	Migraine: Epidemiology, Impact, and Risk Factors for Progression. Headache, 2005, 45, S3-S13.	1.8	317
134	Behavioral Headache Treatment: History, Review of the Empirical Literature, and Methodological Critique. Headache, 2005, 45, S92-S109.	1.8	196
135	Functional Assessment in Migraine (FAIM) Questionnaire: Development of an Instrument Based Upon the WHO's International Classification of Functioning, Disability, and Health. Value in Health, 2005, 8, 591-600.	0.1	26
136	Can we Develop Neurally Acting Drugs for the Treatment of Migraine?. Nature Reviews Drug Discovery, 2005, 4, 741-750.	21.5	64
137	Use of a structured migraine diary improves patient and physician communication about migraine disability and treatment outcomes. International Journal of Clinical Practice, 2005, 59, 281-286.	0.8	33
138	Optimizing the Diagnosis and Treatment of Migraine. Journal of the American Academy of Nurse Practitioners, 2005, 17, 309-317.	1.4	17
139	A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research, 2005, 5, 3.	0.9	102
140	The patients' perceptions of migraine and chronic daily headache: a qualitative study. Journal of Headache and Pain, 2005, 6, 40-47.	2.5	39
141	A validation study of an Italian version of the ID Migraine: preliminary results. Journal of Headache and Pain, 2005, 6, 216-219.	2.5	11
142	Topiramate in migraine prophylaxis. Neurological Sciences, 2005, 26, s130-s133.	0.9	18
143	Migraine headache: Options for acute treatment. Current Neurology and Neuroscience Reports, 2005, 5, 86-92.	2.0	11
144	What is the impact, prevalence, disability, and quality of life of pediatric headache?. Current Pain and Headache Reports, 2005, 9, 341-344.	1.3	37
145	Secular Changes in Health Care Utilization and Work Absence for Migraine and Tension-type Headache: A Population Based Study. European Journal of Epidemiology, 2005, 20, 1007-1014.	2.5	71
146	Prevalence and Burden of Illness of Migraine in Managed Care Patients. Journal of Managed Care Pharmacy, 2005, 11, 124-136.	2.2	8
147	Topiramate: the evidence for its therapeutic value in the prevention of migraine. Core Evidence, 2005, Volume 1-Issues 1 & 2, 0-0.	4.7	0
148	Refractoriness in migraine treatment: what are we talking about?. Expert Review of Neurotherapeutics, 2005, 5, 557-559.	1.4	4
149	How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Current Medical Research and Opinion, 2005, 21, 413-424.	0.9	32

#	Article	IF	CITATIONS
150	Risk of preeclampsia in relation to maternal history of migraine headaches. Journal of Maternal-Fetal and Neonatal Medicine, 2005, 18, 167-172.	0.7	51
151	Therapeutic options in the management of headache attributed to rhinosinusitis. Expert Opinion on Pharmacotherapy, 2005, 6, 715-722.	0.9	4
152	Prevalence, Pattern and Predictors of use of Complementary and Alternative Medicine (CAM) in Migraine Patients Attending a Headache Clinic in Italy. Cephalalgia, 2005, 25, 493-506.	1.8	70
153	Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. Mayo Clinic Proceedings, 2005, 80, 908-916.	1.4	97
154	The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Current Medical Research and Opinion, 2005, 21, 1297-1305.	0.9	31
155	Part I: What do patients really need and want from migraine treatment?. Current Medical Research and Opinion, 2005, 21, S3-S7.	0.9	11
156	Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy, 2005, 22, 193-204.	0.2	7
157	Measurement of the Experience of Living with Primary Recurrent Headache. Pain Management Nursing, 2005, 6, 37-44.	0.4	2
158	Sinus Headache, Migraine, and the Otolaryngologist. Otolaryngology - Head and Neck Surgery, 2005, 133, 489-496.	1.1	23
159	Cervicogenic Headache in Patients With Presumed Migraine: Missed Diagnosis or Misdiagnosis?. Journal of Pain, 2005, 6, 700-703.	0.7	46
160	Understanding the Needs of Migraine Patients. Drugs, 2006, 66, 1???8.	4.9	9
161	Does This Patient With Headache Have a Migraine or Need Neuroimaging?. JAMA - Journal of the American Medical Association, 2006, 296, 1274.	3.8	119
162	Tanacetum parthenium and Salix??alba??(Mig-RL??) Combination in??Migraine Prophylaxis. Clinical Drug Investigation, 2006, 26, 287-296.	1.1	32
163	Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: A randomized, placebo-controlled, double-blind, 12-week pilot study. Clinical Therapeutics, 2006, 28, 1002-1011.	1.1	59
164	Migraine Headaches: A Historical Prospective, a Glimpse into the Future, and Migraine Epidemiology. Disease-a-Month, 2006, 52, 367-384.	0.4	13
165	The Pathophysiology of Migraine. Disease-a-Month, 2006, 52, 385-401.	0.4	7
166	Case Series of Four Different Headache Types Presenting as Tooth Pain. Journal of Endodontics, 2006, 32, 1110-1113.	1.4	43
167	An Otolaryngology, Neurology, Allergy, and Primary Care Consensus on Diagnosis and Treatment of Sinus Headache. Otolaryngology - Head and Neck Surgery, 2006, 134, 516-523.	1.1	57

#	Article	IF	CITATIONS
168	Epidemiology of primary and secondary headaches in a Brazilian tertiary-care center. Arquivos De Neuro-Psiquiatria, 2006, 64, 41-44.	0.3	32
169	Headache: Recognizing its impact on quality of life and improving management. British Journal of Neuroscience Nursing, 2006, 2, 441-447.	0.1	1
170	Aberrant Drug-taking Behaviors and Headache: Patient Versus Physician Report. American Journal of Health Behavior, 2006, 30, 475-482.	0.6	8
172	Using Patient-Centered Endpoints to Determine the Cost-Effectiveness of Triptans for Acute Migraine Therapy. American Journal of Therapeutics, 2006, 13, 411-417.	0.5	13
173	Item analysis of the NHANES ADL instrument in a sample of patients reporting frequent severe headaches. Physiotherapy Research International, 2006, 11, 84-92.	0.7	6
174	ls uncertain diagnosis a more frequent reason for referring migraine patients to neurologist than other headache syndromes?. European Journal of Neurology, 2006, 13, 1370-1373.	1.7	5
175	Patterns of Medical Diagnosis and Treatment of Migraine and Probable Migraine in a Health Plan. Cephalalgia, 2006, 26, 43-49.	1.8	40
176	Oral Sumatriptan for the Acute Treatment of Probable Migraine: First Randomized, Controlled Study. Headache, 2006, 46, 115-124.	1.8	20
177	Effects of a Website Designed to Improve the Management of Migraines. Headache, 2006, 46, 92-100.	1.8	25
178	Zolmitriptan Oral Tablet in Migraine Treatment: High Placebo Responses in Adolescents. Headache, 2006, 46, 101-109.	1.8	94
179	A Comment on Acetaminophen, Aspirin, and Caffeine Versus Sumatriptan Succinate in the Early Treatment of Migraine: Results From the ASSET Trial—A Response. Headache, 2006, 46, 341-342.	1.8	5
180	Acupuncture for Chronic Headaches-An Epidemiological Study. Headache, 2006, 46, 632-641.	1.8	39
181	Acetaminophen, Aspirin, and Caffeine in Combination Versus Ibuprofen for Acute Migraine: Results From a Multicenter, Double-Blind, Randomized, Parallel-Group, Single-Dose, Placebo-Controlled Study. Headache, 2006, 46, 444-453.	1.8	100
182	Changing Physician Knowledge, Attitudes, and Beliefs About Migraine: Evaluation of a New Educational Intervention. Headache, 2006, 46, 732-741.	1.8	24
183	Factors Influencing Migraineur-Consulting Behavior in a University Population. Headache, 2006, 46, 742-749.	1.8	14
184	Acute Migraine Treatment: Patterns of Use and Satisfaction in a Clinical Population. Headache, 2006, 46, 773-780.	1.8	48
185	Migraine Changes with Age: IMPACT on Migraine Classification. Headache, 2006, 46, 1161-1171.	1.8	101
186	Migraine Care Among Different Ethnicities: Do Disparities Exist?. Headache, 2006, 46, 754-765.	1.8	59

#	Article	IF	CITATIONS
187	Imaging Findings of Migraine. Headache, 2006, 46, 1095-1107.	1.8	40
188	Long-Term Migraine Prevention With Topiramate: Open-Label Extension of Pivotal Trials. Headache, 2006, 46, 1151-1160.	1.8	58
189	Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention Study. Headache, 2006, 47, 061117080657014-???.	1.8	352
190	Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet. International Journal of Clinical Practice, 2006, 60, 1530-1535.	0.8	9
191	The Experiences of Midlife Women With Migraines. Journal of Nursing Scholarship, 2006, 38, 278-285.	1.1	25
192	The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura. Journal of Neurology, 2006, 253, 1589-1593.	1.8	34
193	Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2595-2598.	1.0	51
194	Are the headache guidelines useful in therapeutic decisions for primary care physicians, general neurologists, and headache specialists?. Current Treatment Options in Neurology, 2006, 8, 33-41.	0.7	0
195	Topiramate for Migraine Prevention. Pharmacotherapy, 2006, 26, 375-387.	1.2	35
196	Optimizing migraine therapy: evidence-based and patient-centered care. Expert Review of Neurotherapeutics, 2006, 6, 911-919.	1.4	17
197	Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Review of Neurotherapeutics, 2006, 6, 283-289.	1.4	29
198	Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. Current Medical Research and Opinion, 2006, 22, 1535-1544.	0.9	15
199	Predictive model for the Migraine-ACT questionnaire in primary care. Current Medical Research and Opinion, 2007, 23, 3033-3039.	0.9	13
200	Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 2007, 68, 343-349.	1.5	1,943
203	Relationship Between Habitual Refractive Errors and Headache Complaints in Schoolchildren. Optometry and Vision Science, 2007, 84, 137-143.	0.6	31
204	Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: A randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2007, 29, 99-109.	1.1	36
205	Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clinical Therapeutics, 2007, 29, 2511-2519.	1.1	18
206	Choice of Words in Doctor–Patient Communication: An Analysis of Health-Related Internet Sites. Health Communication, 2007, 21, 267-277.	1.8	44

	CITATION RE	PORT	
#	Article	IF	CITATIONS
207	Management of migraine in Australian general practice. Medical Journal of Australia, 2007, 187, 142-146.	0.8	22
208	The Sinus, Allergy and Migraine Study (SAMS) Headache, 2007, 47, 213-224.	1.8	186
209	Headaches and Oral Contraceptives: Impact of Eliminating the Standard 7-Day Placebo Interval. Headache, 2007, 47, 27-37.	1.8	131
210	Coenzyme Q10 Deficiency and Response to Supplementation in Pediatric and Adolescent Migraine. Headache, 2007, 47, 73-80.	1.8	164
211	Ten Lessons on the Epidemiology of Migraine. Headache, 2007, 47, S2-S9.	1.8	78
212	Determinants of Migraine Emergency Department Utilization in the Georgia Medicaid Population Headache, 2007, 47, 1326-1333.	1.8	8
213	An Expert System for Headache Diagnosis: The Computerized Headache Assessment Tool (CHAT). Headache, 2008, 48, 72-78.	1.8	32
214	The Burden of Headache in Neurology Outpatient Clinics in Turkey. Pain Practice, 2007, 7, 313-323.	0.9	24
215	Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study. European Journal of Neurology, 2007, 14, 1079-1084.	1.7	18
216	Probable Migraine in the United States: Results Of The American Migraine Prevalence and Prevention (AMPP) Study. Cephalalgia, 2007, 27, 220-229.	1.8	135
217	Patterns of Triptans Use: A Study Based on the Records of a Community Pharmaceutical Department. Cephalalgia, 2007, 27, 1000-1004.	1.8	33
218	The GRIM2005 Study of Migraine Consultation in France I. Determinants of Consultation for Migraine Headache in France. Cephalalgia, 2007, 27, 1386-1397.	1.8	42
219	Under-diagnosis of common chronic diseases: prevalence and impact on human health. International Journal of Clinical Practice, 2007, 61, 1569-1579.	0.8	57
220	Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk) Tj ETQq1	1 02 8431	4 ੴ BT /Ov∘
221	The validation of ID migraineâ"¢ screener in neurology outpatient clinics in Turkey. Journal of Headache and Pain, 2007, 8, 217-223.	2.5	24
223	Headache attributed to hypothyroidism. Current Pain and Headache Reports, 2007, 11, 304-309.	1.3	25
224	Epidemiology and diagnosis of migraine in children. Current Pain and Headache Reports, 2007, 11, 375-382.	1.3	34
225	Chronic pain rehabilitation in chronic headache disorders. Current Neurology and Neuroscience Reports, 2008, 8, 94-99.	2.0	11

ARTICLE IF CITATIONS # Chronic daily headache: When to suspect sinus disease. Current Pain and Headache Reports, 2008, 12, 226 1.3 4 45-49. In-office Discussions of Migraine: Results from the American Migraine Communication Study. Journal of General Internal Medicine, 2008, 23, 1145-1151. 1.3 Triptans in the Italian population: a drug utilization study and a literature review. Journal of 228 2.5 26 Headache and Pain, 2008, 9, 71-76. Meeting patient expectations in migraine treatment: what are the key endpoints?. Journal of Headache and Pain, 2008, 9, 207-213. Development of a self-reporting questionnaire, BURMIG, to evaluate the burden of migraine. Journal 230 2.5 11 of Headache and Pain, 2008, 9, 309-315. Olanzapine versus Droperidol for the Treatment of Primary Headache in the Emergency Department. 0.8 Academic Emergency Medicine, 2008, 15, 806-811. Treatment of Sinus Headache as Migraine: The Diagnostic Utility of Triptans. Laryngoscope, 2008, 118, 233 1.1 53 2235-2239. Migraine Frequency and Health Utilities: Findings from a Multisite Survey. Value in Health, 2008, 11, 234 0.1 315-321. Results of Screening With the Brief Headache Screen Compared With a Modified 235 1.8 20 IDMigraineTM. Headache, 2008, 48, 385-394. The Prevalence and Impact of Migraine on US Military Officer Trainees. Headache, 2008, 48, 883-889. 1.8 A Migraine Prophylaxis Educational Intervention in a Medicaid Population. Headache, 2008, 48, 267-271. 237 1.8 6 Responsiveness of Migraineâ€ACT and MIDAS Questionnaires for Assessing Migraine Therapy. Headache, 1.8 2008, 48, 1349-1355 The Headache Management Trial: A Randomized Study of Coordinated Care. Headache, 2008, 48, 239 1.8 57 1294-1310. Expert Opinion: Migraine, Psychiatric Comorbidities, and Treatment. Headache, 2008, 48, 952-958. 240 1.8 14 A Randomized Doubleâ€Blind Study Comparing Rizatriptan, Dexamethasone, and the Combination of Both 241 1.8 45 in the Acute Treatment of Menstrually Related Migraine. Headache, 2008, 48, 1286-1293. A Pivotal Moment in 50 Years of Headache History: The First American Migraine Study. Headache, 2008, 242 1.8 48,730-731. 243 A Response from the Authors. Headache, 2008, 48, 732-732. 1.8 0 Refractory Headache: Historical Perspective, Need, and Purposes for an Operational Definition. 244 1.8 Headache, 2008, 48, 770-777.

#	Article	IF	CITATIONS
245	Prevalence and Impact of Migraine Among US Army Soldiers Deployed in Support of Operation Iraqi Freedom. Headache, 2008, 48, 876-882.	1.8	54
246	Analysis of Safety and Tolerability Data Obtained from Over 1,500 Patients Receiving Topiramate for Migraine Prevention in Controlled Trials. Pain Medicine, 2008, 9, 175-185.	0.9	49
247	Early vs. Non-Early Intervention in Acute Migraine — â€~Act When Mild (AwM)'. A Double-Blind, Placebo-Controlled Trial of Almotriptan. Cephalalgia, 2008, 28, 383-391.	1.8	168
248	Clinical Features of Primary Headache in Children: A Multicentre Hospital-Based Study in France. Cephalalgia, 2008, 28, 1145-1153.	1.8	18
249	Evidencias en el tratamiento de la migraña. FMC Formacion Medica Continuada En Atencion Primaria, 2008, 15, 43-53.	0.0	0
251	Sleep and Quality of Life in Clinical Medicine. , 2008, , .		32
252	Neurovascular Pains: Implications of Migraine for the Oral and Maxillofacial Surgeon. Oral and Maxillofacial Surgery Clinics of North America, 2008, 20, 221-235.	0.4	24
253	Survey to evaluate diagnosis and management of headache in primary care: Headache Management Pattern programme. Current Medical Research and Opinion, 2008, 24, 3413-3422.	0.9	15
254	Migraine and possible facial variants (neurovascular orofacial pain). , 2008, , 193-224.		3
255	Phase 1 of Integrated EMDR An Abortive Treatment for Migraine Headaches. Journal of EMDR Practice and Research, 2008, 2, 15-25.	0.2	34
256	Prevalence and characteristics of allodynia in headache sufferers. Neurology, 2008, 70, 1525-1533.	1.5	320
257	Impact of pharmacist interventions on seeking of medical care by migraineurs. Journal of the American Pharmacists Association: JAPhA, 2008, 48, 32-41a.	0.7	5
258	Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ: British Medical Journal, 2008, 337, a636-a636.	2.4	211
259	Migraine-preventive medications: Ensuring their appropriate use. Journal of the American Pharmacists Association: JAPhA, 2008, 48, e107-e124.	0.7	4
261	GPs' classification of headache: is primary headache underdiagnosed?. British Journal of General Practice, 2008, 58, 102-104.	0.7	61
262	What is the impact of physician communication and patient understanding in the management of headache?. Neuropsychiatric Disease and Treatment, 2008, Volume 3, 893-897.	1.0	5
263	Tension-Type, the Forgotten Headache A Common but under Treated Condition. TAJ Journal of Teachers Association, 2009, 17, 121-128.	0.1	0
264	Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update. Therapeutics and Clinical Risk Management, 2009, 5, 661.	0.9	11

ARTICLE IF CITATIONS # General practice physician knowledge about headache: evaluation of the municipal continual medical 265 0.3 14 education program. Arquivos De Neuro-Psiquiatria, 2009, 67, 595-599. The triptans. Expert Review of Neurotherapeutics, 2009, 9, 649-659. 1.4 Allodynia in migraine: frequent random association or unavoidable consequence?. Expert Review of 267 1.4 42 Neurotherapeutics, 2009, 9, 395-408. Rizatriptan Induced Acute on Top of Chronic Ischemic Colitis. American Journal of Gastroenterology, 268 2009, 104, 2643-2644. When the Left Got Left Behind. American Journal of Gastroenterology, 2009, 104, 2644-2645. 269 0.2 0 Headache in general practice., 2009, , 3-11. The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United 271 1.4 83 States and Suggestions for Future Research. Mayo Clinic Proceedings, 2009, 84, 436-445. 1 Calcitonin Gene-Related Peptide Receptor Antagonists for the Treatment of Migraine. Progress in 4.1 Medicinal Chemistry, 2009, 47, 1-35. Chronic pain rehabilitation in chronic headache disorders. Current Pain and Headache Reports, 2009, 273 1.3 4 13, 67-72. 274 Clinical Relevance of Efficacy Endpoints in OTC Headache Trials. Headache, 2009, 49, 646-654. 1.8 Diagnostic Delay and Suboptimal Management in a Referral Population With Hemicrania Continua. 275 1.8 57 Headache, 2009, 49, 227-234. 276 Prevalence and Burden of Headache and Migraine in Germany. Headache, 2009, 49, 79-89. 1.8 133 Intravenous Lidocaine in the Treatment of Refractory Headache: A Retrospective Case Series. Headache, 277 1.8 48 2009, 49, 286-291. Development and Construct Validation of the Pharmacists' Care of Migraineurs Scale. Headache, 2009, 278 1.8 49, 54-63. Migraine in the Triptan Era: Lessons From Epidemiology, Pathophysiology, and Clinical Science. 279 1.8 47 Headache, 2009, 49, S21-33. Predictors of Adherence to Triptans: Factors of Sustained vs Lapsed Users. Headache, 2009, 49, 386-394. 280 1.8 An Internetâ€Based Migraine Headache Diary: Issues in Internetâ€Based Research. Headache, 2009, 49, 281 1.8 32 673-686. Barriers to Satisfactory Migraine Outcomes. What Have We Learned, Where Do We Stand?. Headache, 1.8 2009, 49, 1028-1041.

#	Article	IF	CITATIONS
283	Topiramate for Migraine Prevention in a Naturalistic Setting: Results From an Open Label, Flexible Dose Study. Headache, 2009, 49, 1454-1465.	1.8	11
284	A Comparative ID Migraineâ,,¢ Screener Study in Ophthalmology, ENT and Neurology Out-Patient Clinics. Cephalalgia, 2009, 29, 68-75.	1.8	15
285	Agreement of Self-Reported Migraine With ICHD-II Criteria in the Women's Health Study. Cephalalgia, 2009, 29, 1086-1090.	1.8	82
286	Underdiagnosis and Undertreatment of Migraine in Italy: A Survey of Patients Attending for The First Time 10 Headache Centres. Cephalalgia, 2009, 29, 1285-1293.	1.8	103
287	Evaluating the Use and Timing of Opioids for the Treatment of Migraine Headaches in the Emergency Department. Journal of Emergency Medicine, 2009, 36, 333-337.	0.3	32
288	N-methyl-d-aspartate receptor antagonists for migraine: A potential therapeutic approach. Medical Hypotheses, 2009, 72, 603-605.	0.8	7
289	Migraine headaches: Diagnosis and management. Optometry - Journal of the American Optometric Association, 2009, 80, 138-148.	0.6	11
290	The Epidemiology, Burden, and Comorbidities of Migraine. Neurologic Clinics, 2009, 27, 321-334.	0.8	253
291	The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity. CNS Drugs, 2009, 23, 727-738.	2.7	20
292	ACGME competencies in neurology. Neurology, 2009, 72, 893-898.	1.5	16
292 293	ACGME competencies in neurology. Neurology, 2009, 72, 893-898. Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408.	1.5 0.5	16 12
	Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain		
293	Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408. Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy,	0.5	12
293 294	Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408. Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy, 2009, 26, 114-123.	0.5	12 7
293 294 295	 Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408. Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy, 2009, 26, 114-123. A Candidate Gene Association Study of 77 Polymorphisms in Migraine. Journal of Pain, 2009, 10, 759-766. Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting. 	0.5 0.2 0.7	12 7 47
293 294 295 296	 Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408. Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy, 2009, 26, 114-123. A Candidate Gene Association Study of 77 Polymorphisms in Migraine. Journal of Pain, 2009, 10, 759-766. Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting. Emergency Medicine Clinics of North America, 2009, 27, 71-87. The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United 	0.5 0.2 0.7 0.5	12 7 47 75
293 294 295 296 297	 Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature. Journal of Pain and Palliative Care Pharmacotherapy, 2009, 23, 396-408. Art and Migraine: Researching the Relationship Between Artmaking and Pain Experience. Art Therapy, 2009, 26, 114-123. A Candidate Gene Association Study of 77 Polymorphisms in Migraine. Journal of Pain, 2009, 10, 759-766. Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting. Emergency Medicine Clinics of North America, 2009, 27, 71-87. The Impact of Migraine and the Effect of Migraine Treatment on Workplace Productivity in the United States and Suggestions for Future Research. Mayo Clinic Proceedings, 2009, 84, 436-445. Foods and Supplements in the Management of Migraine Headaches. Clinical Journal of Pain, 2009, 25, 	0.5 0.2 0.7 0.5 1.4	12 7 47 75 57

#	Article	IF	CITATIONS
301	Migraineurs' perceptions of and interactions with pharmacists: a qualitative study. International Journal of Pharmacy Practice, 2010, 16, 357-363.	0.3	9
302	Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting. Journal of Headache and Pain, 2010, 11, 33-44.	2.5	13
303	Long-term effects of a sensitisation campaign on migraine: the Casilino study. Journal of Headache and Pain, 2010, 11, 129-135.	2.5	2
304	Factors related to pharmacists' care of migraineurs. Research in Social and Administrative Pharmacy, 2010, 6, 232-245.	1.5	5
305	Sleep duration, vital exhaustion and perceived stress among pregnant migraineurs and non-migraineurs. BMC Pregnancy and Childbirth, 2010, 10, 72.	0.9	13
306	Headache. Neurotherapeutics, 2010, 7, 149-152.	2.1	2
307	The Use of Migraine Preventive Medications Among Patients with and without Migraine Headaches. Cephalalgia, 2010, 30, 97-104.	1.8	35
308	Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine. Cephalalgia, 2010, 30, 425-432.	1.8	65
309	A survey of family doctors on the likeability of migraine and other common diseases and their prevalence of migraine. Cephalalgia, 2010, 30, 620-623.	1.8	10
310	Migraine Education Improves Quality of Life in a Primary Care Setting. Headache, 2010, 50, 600-612.	1.8	57
311	A Randomized, Placeboâ€Controlled Trial of Acetaminophen for Treatment of Migraine Headache. Headache, 2010, 50, 819-833.	1.8	43
312	Migraine and Migraines of Specialists: Perceptions and Management. Headache, 2010, 50, 1115-1125.	1.8	20
313	Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START*study. International Journal of Clinical Practice, 2010, 64, 936-943.	0.8	14
314	NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals, 2010, 3, 1966-1987.	1.7	50
315	Effectiveness and Safety of Rizatriptan Benzoate 10 mg in the Treatment of Migraine Headaches. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S4670.	0.4	0
316	The associations of migraines and other headaches with work performance: Results from the National Comorbidity Survey Replication (NCS-R). Cephalalgia, 2010, 30, 722-734.	1.8	12
317	Development and validation of the EUROLIGHT questionnaire to evaluate the burden of primary headache disorders in Europe. Cephalalgia, 2010, 30, 1082-1100.	1.8	38
318	Small- and Moderate-Size Right-to-Left Shunts Identified by Saline Contrast Echocardiography Are Normal and Unrelated to Migraine Headache. Chest, 2010, 138, 264-269.	0.4	57

#	Article	IF	CITATIONS
319	The social impact and burden of headache. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 23-32.	1.0	4
320	Acute Treatment of Migraine Headaches. Seminars in Neurology, 2010, 30, 145-153.	0.5	5
321	Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine. CNS Drugs, 2010, 24, 695-712.	2.7	19
322	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines. Annals of Pharmacotherapy, 2010, 44, 360-366.	0.9	31
323	TRPV1 in migraine pathophysiology. Trends in Molecular Medicine, 2010, 16, 153-159.	3.5	90
324	Epidemiological and clinical aspects of migraine in users of combined oral contraceptives. Contraception, 2010, 81, 202-208.	0.8	40
325	Childhood Periodic Syndromes: A Population-Based Study. Pediatric Neurology, 2010, 43, 420-424.	1.0	35
326	OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine. Expert Opinion on Biological Therapy, 2010, 10, 289-298.	1.4	9
327	Prescription patterns in preventive and abortive migraine medication. Cephalalgia, 2011, 31, 1659-1663.	1.8	11
328	The Female Athlete: The Role of Gender in the Assessment and Management of Sport-Related Concussion. Clinics in Sports Medicine, 2011, 30, 125-131.	0.9	89
329	The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: A post-hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia, 2011, 31, 1466-1476.	1.8	31
330	Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia, 2011, 31, 301-315.	1.8	467
331	A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns. Neuropsychiatric Disease and Treatment, 2011, 7, 663.	1.0	22
332	Invasive and Non-invasive Methods in Diagnostic of Migraine: a Literature Review. Acta Chirurgica Latviensis, 2011, 11, 134-138.	0.2	0
333	MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine. Headache, 2011, 51, 507-517.	1.8	84
334	Acceptance, appraisals, and coping in relation to migraine headache: an evaluation of interrelationships using daily diary methods. Journal of Behavioral Medicine, 2011, 34, 307-320.	1.1	48
335	EuroQol (EQ-5D) health utility scores for patients with migraine. Quality of Life Research, 2011, 20, 601-608.	1.5	47
336	Identification of molecular genetic factors that influence migraine. Molecular Genetics and Genomics, 2011, 285, 433-446.	1.0	48

#	Article	IF	CITATIONS
337	Causes of headache in patients with a primary diagnosis of sinus headache. European Archives of Oto-Rhino-Laryngology, 2011, 268, 1593-1596.	0.8	38
338	Discovery of potent, cyclic calcitonin geneâ€related peptide receptor antagonists. Journal of Peptide Science, 2011, 17, 383-386.	0.8	10
339	Validation of the Headache Impact Test (HIT-6â,,¢) across episodic and chronic migraine. Cephalalgia, 2011, 31, 357-367.	1.8	350
340	The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. Cephalalgia, 2011, 31, 1116-1130.	1.8	59
341	Headache. Seminars in Neurology, 2011, 31, 005-017.	0.5	18
342	Migraine and migraine subtypes in preadolescent children. Neurology, 2012, 79, 1881-1888.	1.5	117
343	How general practitioners treat migraine patients—evaluation of a headache guideline. Cephalalgia, 2012, 32, 908-915.	1.8	6
344	Acupuncture for migraine prophylaxis: a randomized controlled trial. Cmaj, 2012, 184, 401-410.	0.9	138
345	Before the headache. Neurology, 2012, 79, 1392-1396.	1.5	62
346	Tension-Type Headache. CONTINUUM Lifelong Learning in Neurology, 2012, 18, 823-834.	0.4	13
347	Low rate of self-awareness and medical recognition of migraine in Germany. Cephalalgia, 2012, 32, 1023-1030.	1.8	17
348	A Randomized Controlled Trial of a Comprehensive Migraine Intervention Prior to Discharge From an Emergency Department. Academic Emergency Medicine, 2012, 19, 1151-1157.	0.8	11
349	Acidâ€sensing ion channel 1: A novel therapeutic target for migraine with aura. Annals of Neurology, 2012, 72, 559-563.	2.8	95
350	Migraine with aura in patients over 50Âyears of age: the Marseille's registry. Journal of Neurology, 2012, 259, 1868-1873.	1.8	16
351	Multidisciplinary integrated headache care: a prospective 12-month follow-up observational study. Journal of Headache and Pain, 2012, 13, 521-529.	2.5	55
352	Depression and risk of transformation of episodic to chronic migraine. Journal of Headache and Pain, 2012, 13, 615-624.	2.5	214
353	Primary headache syndromes and sinus headache: An approach to diagnosis and management. Auris Nasus Larynx, 2012, 39, 257-260.	0.5	9
354	Design and synthesis of potent antagonists containing rigid spirocyclic privileged structures for the CGRP receptor. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4719-4722.	1.0	12

#	Article	IF	CITATIONS
355	Migraine diagnosis: Screening items, instruments, and scales. Acta Anaesthesiologica Taiwanica, 2012, 50, 69-73.	1.0	41
356	Diagnosis and treatment status of migraine: A clinic-based study in China. Journal of the Neurological Sciences, 2012, 315, 89-92.	0.3	15
357	Endoscopic neural blockade for rhinogenic headache and facial pain: 2011 update. International Forum of Allergy and Rhinology, 2012, 2, 325-330.	1.5	6
358	Validation of criterion-based patient assignment and treatment effectiveness of a multidisciplinary modularized managed care program for headache. Journal of Headache and Pain, 2012, 13, 379-387.	2.5	11
359	Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. Headache, 2012, 52, 3-17.	1.8	174
360	Validating Migraineâ€Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine. Headache, 2012, 52, 409-421.	1.8	98
361	Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. Headache, 2012, 52, 213-223.	1.8	25
362	A Populationâ€Based Longitudinal Community Study of Major Depression and Migraine. Headache, 2012, 52, 422-432.	1.8	65
363	Sumatriptanâ€Naproxen and Butalbital: A Doubleâ€Blind, Placeboâ€Controlled Crossover Study. Headache, 2012, 52, 530-543.	1.8	22
364	Chronic Pain and Depression in the Quality of Life of Women With Migraine – A Controlled Study. Headache, 2012, 52, 400-408.	1.8	21
365	Stability, Responsiveness, and Reproducibility of a Visual Analog Scale for Treatment Satisfaction in Migraine. Headache, 2012, 52, 1005-1018.	1.8	8
366	Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study. Headache, 2012, 52, 1456-1470.	1.8	389
367	Adherence with Migraine Prophylaxis in Clinical Practice. Pain Practice, 2012, 12, 541-549.	0.9	91
368	One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults. Journal of Headache and Pain, 2012, 13, 147-157.	2.5	135
369	Headache in the world: public health and research priorities. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 51-57.	0.7	15
370	A computerized expert system for diagnosing primary headache based on International Classification of Headache Disorder (ICHD-II). SpringerPlus, 2013, 2, 199.	1.2	6
371	Impact of <scp>NSAID</scp> and Triptan Use on Developing Chronic Migraine: Results From the <scp>A</scp> merican Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2013, 53, 1548-1563.	1.8	53
372	Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Value in Health, 2013, 16, 31-38.	0.1	99

#	Article	IF	CITATIONS
373	Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. Journal of Headache and Pain, 2013, 14, 47.	2.5	43
374	Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe <scp>H</scp> eadache: Results of the <scp>A</scp> merican Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2013, 53, 1278-1299.	1.8	330
375	Sumatriptan Iontophoretic Transdermal System: History, Study Results, and Use in Clinical Practice. Headache, 2013, 53, 34-42.	1.8	9
376	Migraine, triptans, and the risk of developing rosacea. Journal of the American Academy of Dermatology, 2013, 69, 399-406.	0.6	46
377	Botulinum toxins: Mechanisms of action, antinociception and clinical applications. Toxicology, 2013, 306, 124-146.	2.0	142
378	Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2013, 131, 1350-1360.	1.5	189
379	Comparison of Anxiety, Depression, Stress and Anger in Migraine, Diabetic and Cardiac Patients and Healthy People. Procedia, Social and Behavioral Sciences, 2013, 84, 1885-1888.	0.5	2
380	An Investigation of The Effectiveness of a Composed Model of Cognitive-behavior Headache Management on the Treatment of Anxiety, Depression, Stress and Migraine Symptoms. Procedia, Social and Behavioral Sciences, 2013, 84, 1850-1855.	0.5	2
381	Frequency and Burden of Headacheâ€Related Nausea: Results From the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention (<scp>AMPP</scp>) Study. Headache, 2013, 53, 93-103.	1.8	59
382	Migraine and multiple sclerosis: Epidemiology and approach to treatment. Multiple Sclerosis and Related Disorders, 2013, 2, 73-79.	0.9	22
383	The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the <scp>U</scp> nited <scp>S</scp> tates: A Review of Statistics From National Surveillance Studies. Headache, 2013, 53, 427-436.	1.8	319
384	Illness perception of migraineurs from the general population. Psychology and Health, 2013, 28, 384-398.	1.2	6
385	Interdisciplinary management of headache disorders. Techniques in Regional Anesthesia and Pain Management, 2013, 17, 174-187.	0.2	4
386	Healthcare resource utilization and direct costs associated with frequent nausea in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Journal of Medical Economics, 2013, 16, 490-499.	1.0	13
387	Cluster headache is associated with an increased risk of depression: A nationwide population-based cohort study. Cephalalgia, 2013, 33, 182-189.	1.8	44
388	Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. Neurology, 2013, 81, 431-436.	1.5	83
389	The American Academy of Neurology's Top Five Choosing Wisely recommendations. Neurology, 2013, 81, 1022-1023.	1.5	37
390	The American Academy of Neurology's Top Five Choosing Wisely recommendations. Neurology, 2013, 81, 1004-1011.	1.5	85

#	Article	IF	CITATIONS
391	Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. Acta Neurologica Scandinavica, 2013, 128, 65-72.	1.0	19
392	A Retrospective Matched Case-Control Study on Medical Costs of Refractory Migraine in Taiwan. Headache, 2013, 53, 526-539.	1.8	8
393	Migraine Management in Community Pharmacies: Practice Patterns and Knowledge of Pharmacy Personnel in <scp>T</scp> hailand. Headache, 2013, 53, 1451-1463.	1.8	15
394	Tension-type headache. , 0, , 21-29.		0
395	Alcohol use problems in migraine and tension-type headache. Arquivos De Neuro-Psiquiatria, 2014, 72, 24-27.	0.3	6
396	Headache Management. , 2014, , 408-423.e4.		0
397	Sumatriptan Transdermal System Can Be Correctly Assembled and Applied During Migraine Attacks. Headache, 2014, 54, 850-860.	1.8	7
398	Reliability and Validity of the Persian <scp>HIT</scp> â€6 Questionnaire in Migraine and Tensionâ€ŧype Headache. Pain Practice, 2014, 14, 625-631.	0.9	32
399	Consistency of Return to Normal Function, Productivity, and Satisfaction Following Migraine Attacks Treated With Sumatriptan/Naproxen Sodium Combination. Headache, 2014, 54, 640-654.	1.8	8
400	Retrospective Outcome Analyses for Headaches in a Pain Rehabilitation Interdisciplinary Program. Headache, 2014, 54, 520-527.	1.8	11
401	A Critical Evaluation of Migraine Trigger Site Deactivation Surgery. Headache, 2014, 54, 142-152.	1.8	37
402	Headache from the Doctors' Perspective. European Neurology, 2014, 71, 157-164.	0.6	6
403	Identifying the Factors Underlying Discontinuation of Triptans. Headache, 2014, 54, 278-289.	1.8	42
404	Results of a multicenter, double-blind, randomized, parallel-group, placebo-controlled, single-dose study comparing the fixed combination of acetaminophen, acetylsalicylic acid, and caffeine with ibuprofen for acute treatment of patients with severe migraine. Cephalalgia, 2014, 34, 1070-1078.	1.8	25
405	Orofacial Pain. , 2014, , .		10
406	Improving the Classification of Migraine Subtypes: An Empirical Approach Based on Factor Mixture Models in the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention (<scp>AMPP</scp>) Study. Headache, 2014, 54, 830-849.	1.8	32
407	Sumatriptan iontophoretic transdermal system. Neurology: Clinical Practice, 2014, 4, 454-457.	0.8	6
409	Impact of Preoperative Narcotic Use on Outcomes in Migraine Surgery. Plastic and Reconstructive Surgery, 2014, 134, 113-119.	0.7	15

#	Article	IF	CITATIONS
410	Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headacheâ€Related Disability: Results From the American Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2015, 55, 825-839.	1.8	20
411	Validation of the Chinese Version of ID-Migraine in Medical Students and Systematic Review with Meta-Analysis Concerning Its Diagnostic Accuracy. Journal of Oral and Facial Pain and Headache, 2015, 29, 265-278.	0.7	19
412	The Prevalence and Awareness of Migraine Among University Students in Harbin, China. Journal of Oral and Facial Pain and Headache, 2015, 29, 384-389.	0.7	13
413	Are migraine and tension-type headache diagnostic types or points on a severity continuum? An exploration of the latent taxometric structure of headache. Pain, 2015, 156, 1200-1207.	2.0	28
414	Persistent Frequent Nausea Is Associated With Progression to Chronic Migraine: <scp>AMPP</scp> Study Results. Headache, 2015, 55, 76-87.	1.8	46
415	The management of the patient with headache: from evidence to clinical practice. Italian Journal of Medicine, 2015, 9, 37.	0.2	2
416	A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine. International Journal of General Medicine, 2015, 8, 27.	0.8	6
417	Overview of Migraine. , 2015, , 41-49.		0
418	Tension-Type Headache. , 2015, , 149-160.		3
419	Burden of migraine related to menses: results from the AMPP study. Journal of Headache and Pain, 2015, 16, 24.	2.5	60
420	Recalled maltreatment, migraine, and tension-type headache. Neurology, 2015, 84, 132-140.	1.5	66
421	The place of corticosteroids in migraine attack management: A 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia, 2015, 35, 996-1024.	1.8	57
422	Is migraine a risk factor for pediatric stroke?. Cephalalgia, 2015, 35, 1252-1260.	1.8	41
423	A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. Expert Opinion on Drug Delivery, 2015, 12, 1565-1577.	2.4	20
424	Symptomatic Overlap and Therapeutic Opportunities in Primary Headache. Journal of Pharmacy Practice, 2015, 28, 413-418.	0.5	1
425	Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology, 2015, 84, 688-695.	1.5	219
426	Advanced Headache Therapy. , 2015, , .		1
427	Attentionâ€deficit/hyperactivity disorder symptoms in adults with selfâ€reported epilepsy: Results from a national epidemiologic survey of epilepsy. Epilepsia, 2015, 56, 218-224.	2.6	37

#	Article	IF	CITATIONS
428	Psychosocial Adjustment of Children With Migraine and Tension‶ype Headache – A Nationwide Study. Headache, 2015, 55, 39-50.	1.8	41
429	Acute Treatment Optimization in Episodic and Chronic Migraine: Results of the <scp>A</scp> merican <scp>M</scp> igraine <scp>P</scp> revalence and <scp>P</scp> revention (<scp>AMPP</scp>) Study. Headache, 2015, 55, 502-518.	1.8	32
430	Preparation and Characterization of Rizatriptan Benzoate Loaded Solid Lipid Nanoparticles for Brain Targeting. Materials Today: Proceedings, 2015, 2, 4521-4543.	0.9	15
431	Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease, 2015, 74, 137-143.	2.1	71
432	The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia, 2015, 35, 563-578.	1.8	203
433	Managing migraine by patient profile: role of frovatriptan. Patient Preference and Adherence, 2016, 10, 501.	0.8	6
434	The Association of Cardiovascular Disease and Migraine: Review. Journal of Clinical & Experimental Cardiology, 2016, 7, .	0.0	3
435	New Advancements in Migraine Assessment and Treatment. Advances in Ophthalmology and Optometry, 2016, 1, 249-260.	0.3	3
436	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clinic Proceedings, 2016, 91, 596-611.	1.4	123
437	Predicting Inadequate Response to Acute Migraine Medication: Results From the <scp>A</scp> merican Migraine Prevalence and Prevention (<scp>AMPP</scp>) Study. Headache, 2016, 56, 1635-1648.	1.8	64
439	Antidepressant Medications. , 2016, , 297-302.		0
440	Management of headache and associated factors among undergraduate medicine and health science students of University of Gondar, North West Ethiopia. Journal of Headache and Pain, 2016, 17, 56.	2.5	37
441	Asthma is a risk factor for new onset chronic migraine: Results from the <scp>A</scp> merican migraine prevalence and prevention study. Headache, 2016, 56, 118-131.	1.8	49
442	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2016, 56, 821-834.	1.8	160
443	Development and Validation of a Fourâ€item Migraine Screening Algorithm Among a Nonclinical Sample: The Migraineâ€4. Headache, 2016, 56, 86-94.	1.8	14
444	Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache, 2016, 56, 292-305.	1.8	73
445	Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Webâ€Based Survey. Headache, 2016, 56, 306-322.	1.8	147
446	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia, 2016, 36, 203-215.	1.8	42

#	Article	IF	CITATIONS
448	Visual processing in migraine. Cephalalgia, 2016, 36, 1057-1076.	1.8	39
449	Intranasal Pharmacokinetic Data for Triptans Such as Sumatriptan and Zolmitriptan Can Render Area Under the Curve (AUC) Predictions for the Oral Route: Strategy Development and Application. Journal of Pain and Palliative Care Pharmacotherapy, 2016, 30, 13-24.	0.5	2
450	Headaches in multiple sclerosis: Cross-sectional study of a multiethnic population. Clinical Neurology and Neurosurgery, 2016, 143, 71-75.	0.6	19
451	Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs, 2016, 30, 245-267.	2.7	4
452	Prevalence of migraine in a diverse community—electronic methods for migraine ascertainment in a large integrated health plan. Cephalalgia, 2016, 36, 325-334.	1.8	24
453	Migraine diagnosis and treatment: A knowledge and needs assessment among primary care providers. Cephalalgia, 2016, 36, 358-370.	1.8	45
454	Migraine and incidence of ischemic stroke: A nationwide population-based study. Cephalalgia, 2017, 37, 327-335.	1.8	55
455	Family Impact of Migraine: Development of the Impact of Migraine on Partners and Adolescent Children (IMPAC) Scale. Headache, 2017, 57, 570-585.	1.8	30
456	A Realâ€World Analysis of Migraine: A Crossâ€Sectional Study of Disease Burden and Treatment Patterns. Headache, 2017, 57, 1532-1544.	1.8	86
457	Framinghamâ€Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2017, 57, 1507-1521.	1.8	51
458	Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clinical Drug Investigation, 2017, 37, 937-946.	1.1	16
459	AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine. Expert Review of Clinical Pharmacology, 2017, 10, 821-832.	1.3	5
460	Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. Headache, 2017, 57, 1026-1040.	1.8	49
461	Multisensory Integration in Migraine: RecentÂDevelopments. Multisensory Research, 2017, 30, 549-563.	0.6	4
462	Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2017, 57, 31-44.	1.8	49
463	Factors Associated with Direct Health Care Costs Among Patients with Migraine. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 1169-1176.	0.5	28
464	Headache of Analgesic Abuse as a Cause of New Pain Pathways Development. , 2017, , .		0
465	Headaches and Facial Pain in Rhinology. American Journal of Rhinology and Allergy, 2018, 32, 12-15.	1.0	12

#	Article	IF	CITATIONS
466	Activation of pial and dural macrophages and dendritic cells by cortical spreading depression. Annals of Neurology, 2018, 83, 508-521.	2.8	59
467	Fundamentals of Pain Medicine. , 2018, , .		5
468	Primary Headaches. , 2018, , 281-290.		0
469	Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. Headache, 2018, 58, 512-524.	1.8	16
470	Primary headaches. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 146, 267-284.	1.0	2
471	The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. Journal of Headache and Pain, 2018, 19, 15.	2.5	23
472	Migraine is common in patients with sarcoidosis. Cephalalgia, 2018, 38, 2079-2082.	1.8	5
473	Age-Related Changes in Headache Days across the Cognitive Spectrum. Pain Medicine, 2018, 19, 1478-1484.	0.9	3
474	Sex differences in sport-related concussion long-term outcomes. International Journal of Psychophysiology, 2018, 132, 9-13.	0.5	57
475	Fast and Selective Simultaneous Determination of Acetaminophen, Aspirin and Caffeine in Pharmaceutical Products by Batch Injection Analysis with Multiple Pulse Amperometric Detection. Electroanalysis, 2018, 30, 296-303.	1.5	11
476	Temporal Integration of Motion Streaks in Migraine. Vision (Switzerland), 2018, 2, 27.	0.5	1
477	Chronic Pain and Overview or Differential Diagnoses of Nonodontogenic Orofacial Pain. Primary Dental Journal, 2018, 7, 71-82.	0.3	13
478	Gallbladder Stone Disease Is Associated with an Increased Risk of Migraines. Journal of Clinical Medicine, 2018, 7, 455.	1.0	5
479	The validation of the Hungarian version of the ID-migraine questionnaire. Journal of Headache and Pain, 2018, 19, 106.	2.5	9
480	Prevalence and Clinical Factors of Migraine in Patients With Spontaneous Coronary Artery Dissection. Journal of the American Heart Association, 2018, 7, e010140.	1.6	63
481	Migraine and cluster headache – the common link. Journal of Headache and Pain, 2018, 19, 89.	2.5	44
482	Multimodal MRI-based classification of migraine: using deep learning convolutional neural network. BioMedical Engineering OnLine, 2018, 17, 138.	1.3	35
483	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. Headache, 2018, 58, 1408-1426.	1.8	106

#	Article	IF	CITATIONS
484	Restless legs syndrome is associated with increased risk of migraine. Cephalalgia Reports, 2018, 1, 251581631878074.	0.2	3
485	Investigating Head Movements Induced by †Riloid' Patterns in Migraine and Control Groups Using AaÂVirtualÂRealityÂDisplay. Multisensory Research, 2018, 31, 753-777.	0.6	2
486	The Effect of Propofol on Chronic Headaches in Patients Undergoing Endoscopy. Pain Research and Management, 2018, 2018, 1-7.	0.7	7
487	Secondary Headaches in Children and Adolescents: What Not to Miss. Current Neurology and Neuroscience Reports, 2018, 18, 61.	2.0	7
488	Measures of Functioning in Patients With Episodic Migraine: Findings From a Doubleâ€Blind, Randomized, Placeboâ€Controlled Phase 2b Trial With Galcanezumab. Headache, 2018, 58, 1225-1235.	1.8	21
489	Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. Journal of Headache and Pain, 2018, 19, 38.	2.5	88
490	Acceptance, Psychiatric Symptoms, and Migraine Disability: An Observational Study in a Headache Center. Headache, 2018, 58, 859-872.	1.8	11
491	Epidemiology of migraine in men: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Cephalalgia, 2019, 39, 296-305.	1.8	34
492	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. Headache, 2019, 59, 1310-1323.	1.8	54
493	The Association Between Parental Migraine and Infant Colic: A Crossâ€ S ectional, Webâ€Based, U.S. Survey Study. Headache, 2019, 59, 988-1001.	1.8	14
494	Does Mindfulnessâ€Based Cognitive Therapy for Migraine Reduce Migraineâ€Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial. Headache, 2019, 59, 1448-1467.	1.8	62
495	Migraine Literacy and Treatment in a University Sample. SN Comprehensive Clinical Medicine, 2019, 1, 749-757.	0.3	6
496	Neurovascular Orofacial Pain. , 2019, , 1983-2004.		0
497	Paranasal sinus volumes and headache: is there a relation?. European Archives of Oto-Rhino-Laryngology, 2019, 276, 2267-2271.	0.8	7
498	Erenumab in chronic migraine with medication overuse. Neurology, 2019, 92, e2309-e2320.	1.5	163
499	Frontal Sinus Surgery. , 2019, , .		5
500	Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey. Journal of Medical Economics, 2019, 22, 849-858.	1.0	12
501	Diagnostic delay and suboptimal management in persistent idiopathic facial pain and persistent dentoalveolar pain; a cross-sectional study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, 127, 498-503.	0.2	11

#	Article	IF	CITATIONS
502	Painful Temporomandibular Disorder Is Associated With Migraine in Adolescents: A Case-Control Study. Journal of Pain, 2019, 20, 1155-1163.	0.7	15
503	Cefalea tensional. Medicine, 2019, 12, 4154-4162.	0.0	0
504	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. Cephalalgia, 2019, 39, 873-882.	1.8	26
505	Migraine Progression: A Systematic Review. Headache, 2019, 59, 306-338.	1.8	198
507	Sleep Disorders Among People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2019, 59, 32-45.	1.8	63
508	When Mom Has Migraine: An Observational Study of the Impact of Parental Migraine on Adolescent Children. Headache, 2019, 59, 224-234.	1.8	12
509	ADHD Is Comorbid to Migraine in Childhood: A Population-Based Study. Journal of Attention Disorders, 2020, 24, 990-1001.	1.5	29
510	Individuals with migraine have a different dry eye symptom profile than individuals without migraine. British Journal of Ophthalmology, 2020, 104, 260-264.	2.1	21
511	Learning Migraine Self-management: The Role of Mothers and Socioeconomic Status. Journal for Nurse Practitioners, 2020, 16, e31-e34.	0.4	2
512	Physical therapist clinical reasoning and classification inconsistencies in headache disorders: a United States survey. Journal of Manual and Manipulative Therapy, 2020, 28, 28-40.	0.7	7
513	Toothâ€Related Pain or Not?. Headache, 2020, 60, 235-246.	1.8	25
514	Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort. European Journal of Neurology, 2020, 27, 536-541.	1.7	47
515	Craniofacial Autonomic Dysfunction in Migraine: Implications for Treatment and Prognosis. Journal of Neuro-Ophthalmology, 2020, 40, 67-73.	0.4	9
516	Celecoxib reduces cortical spreading depression–induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks. Pain, 2020, 161, 1019-1026.	2.0	7
517	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. Headache, 2020, 60, 416-429.	1.8	61
518	Population-Based Health Utility Assessment of Migraine Headache Symptoms before and after Surgical Intervention. Plastic and Reconstructive Surgery, 2020, 145, 210-217.	0.7	1
519	Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache, 2020, 60, 2340-2356.	1.8	47
520	The Effect of Psychiatric Comorbidities on Headacheâ€Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache, 2020, 60, 1683-1696.	1.8	42

#	Article	IF	CITATIONS
521	Premonitory symptoms in glyceryl trinitrate triggered migraine attacks: a case-control study. Pain, 2020, 161, 2058-2067.	2.0	17
522	Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. Journal of Headache and Pain, 2020, 21, 49.	2.5	9
523	Brain Network Integration in Patients with Migraine: A Magnetoencephalography Study. Brain Connectivity, 2020, 10, 224-235.	0.8	6
524	Midfacial pain. Oral Surgery, 2020, 13, 415-421.	0.1	0
525	International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia, 2020, 40, 129-221.	1.8	374
526	Symptom Burden and Profiles in Concussed Children with and without Prolonged Recovery. International Journal of Environmental Research and Public Health, 2020, 17, 351.	1.2	16
527	Characterization of Acute Prescription Migraine Medication Use. Mayo Clinic Proceedings, 2020, 95, 709-718.	1.4	14
528	Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea.		

#	Article	IF	CITATIONS
539	Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation. Neuropharmacology, 2021, 195, 108375.	2.0	11
540	Improvement in visual perception after high-frequency transcranial random noise stimulation (hf-tRNS) in those with migraine: An equivalent noise approach. Neuropsychologia, 2021, 161, 107990.	0.7	6
541	Design, synthesis and biological evaluation of pyridinylmethylenepiperidine derivatives as potent 5-HT1F receptor agonists for migraine therapy. European Journal of Medicinal Chemistry, 2021, 225, 113782.	2.6	5
542	Etiology of â€~Sinus Headache'—Moving the Focus from Rhinology to Neurology. A Systematic Review. Brain Sciences, 2021, 11, 79.	1.1	8
544	The Healthcare Solution to Headache. Headache, 2019, , 203-224.	0.2	4
545	Neurovascular Orofacial Pain. , 2017, , 1-22.		2
546	An Intelligent Systems Approach to Primary Headache Diagnosis. Lecture Notes in Computer Science, 2017, , 61-72.	1.0	12
547	Protocollaire behandeling van patiënten met migraine en spanningshoofdpijn:. , 2004, , 219-260.		8
548	Medication Overuse Headache. , 2011, , 453-463.		1
549	Development of the Cogniphobia Scale for Headache Disorders (CS-HD): A pilot study Psychological Assessment, 2017, 29, 1296-1301.	1.2	11
550	Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers. Headache, 2021, 61, 69-79.	1.8	12
551	Pediatric and Adolescent Headache. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 1108-1136.	0.4	16
552	Self-awareness of migraine. Neurology, 2002, 58, S21-6.	1.5	56
553	Diagnostic lessons from the Spectrum Study. Neurology, 2002, 58, S27-31.	1.5	106
554	The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology, 2002, 58, S3-9.	1.5	76
555	Migraine throughout the life cycle. Neurology, 2004, 62, S2-8.	1.5	41
556	Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology, 2005, 65, S50-8.	1.5	49
557	Genetic Determinants of Cardiovascular Events among Women with Migraine: A Genome-Wide Association Study. PLoS ONE, 2011, 6, e22106.	1.1	20

#	Article	IF	CITATIONS
558	Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Therapeutics and Clinical Risk Management, 2006, 2, 303-308.	0.9	23
559	The Role of TRP Channels in Migraine. Open Pain Journal, 2013, 6, 37-49.	0.4	15
560	Psychological adjustment in children with episodic migraine: A population-based study Psychology and Neuroscience, 2014, 7, 33-41.	0.5	8
561	Different Profile of Propranolol and Amitriptyline Effects on Migraine Prophylaxis. International Journal of Pharmacology, 2005, 1, 366-368.	0.1	6
562	Environmental Effects of Nickel-Copper Exploitation on Workers Health Status at Selebi Phikwe Area, Botswana. Journal of Applied Sciences, 2008, 8, 2344-2356.	0.1	10
563	Preinjury History of Migraine Headache: Effects on Neurocognitive Performance and Symptoms in Athletes With Concussion. Athletic Training & Sports Health Care, 2014, 6, 220-227.	0.4	10
564	Migraine prophylaxis: who, why, and how Cleveland Clinic Journal of Medicine, 2006, 73, 793-794.	0.6	7
565	Factors associated with delayed diagnosis of migraine: A hospital-based cross-sectional study. Journal of Family Medicine and Primary Care, 2019, 8, 1925.	0.3	8
566	Effectiveness of Mindfulness-Based Cognitive-Behavioral Therapy on Relieving Migraine Headaches. Archives of Neuroscience, 2017, In Press, .	0.1	8
567	Impact of a Self-Help Intervention on Performance of Headache Management Behaviors: A Self-Efficacy Approach. Internet Journal of Allied Health Sciences and Practice, 2004, , .	0.2	3
568	Analgesic Rebound Headache. , 2007, , 492-501.		0
569	Headache and the Patient who Failed Primary Sinus Surgery. , 2008, , 217-222.		0
572	CGRP Receptor Antagonists for Migraine: Challenges and Promises. , 2010, , 185-197.		0
575	General Issues Arising from the Use of Drugs for Headache Disorders. , 2011, , 611-617.		0
578	A pilot project to assess community pharmacists' knowledge and caring behaviors for recurrent headache sufferers after a migraine-focused educational intervention. Innovations in Pharmacy, 2014, 5, .	0.2	0
579	When does an adult with headaches need central nervous system imaging?. Cleveland Clinic Journal of Medicine, 2014, 81, 719-720.	0.6	0
581	Prevention of venous thromboembolic events in wounded from firearms-governmental vertebral fractures. European Journal of Biomedical and Life Sciences, 2015, , 10-20.	0.0	0
582	Migraine prevention by noninvasive electrical fastigial nucleus stimulation: a multi-center, randomized, double-blind, sham-controlled trial. Asia Pacific Clinical and Translational Nervous System Diseases, 2016, 1, 107.	0.0	0

#	Article	IF	CITATIONS
583	Clinical Characteristics of Migraine in Twelve Sudanese families. Journal of Neurology & Stroke, 2017, 7, .	0.0	0
584	Clinical characteristics of migraine: A prospective cross-sectional study over nine years. F1000Research, 0, 7, 1973.	0.8	1
585	Barriers to Care. Headache, 2019, , 173-183.	0.2	1
588	Adherence to headache treatment and profile of previous health professional seeking among patients with chronic headache: a retrospective analysis. MedGenMed: Medscape General Medicine, 2007, 9, 21.	0.2	1
589	Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed: Medscape General Medicine, 2007, 9, 53.	0.2	11
590	Acute migraine: Current treatment and emerging therapies. Therapeutics and Clinical Risk Management, 2007, 3, 449-59.	0.9	25
591	The pharmacological management of migraine, part 1: overview and abortive therapy. P and T, 2008, 33, 404-16.	1.0	8
592	Topiramate: the evidence for its therapeutic value in the prevention of migraine. Core Evidence, 2005, 1, 103-24.	4.7	1
593	Ophthalmic beta blockers: treatment for acute migraine?. Missouri Medicine, 2014, 111, 292-3.	0.3	1
594	A pilot analysis of headache disorders in breast cancer patients. Neurological Sciences, 2022, 43, 3313-3320.	0.9	4
595	Knowledge, Attitudes, and Management of General Practitioners of the Hospital Districts of Ouagadougou about Migraine (Burkina Faso). Pain Research and Management, 2021, 2021, 1-8.	0.7	1
597	Migraine in the Emergency Department: A Prospective Multinational Study of Patient Characteristics, Management, and Outcomes. Neuroepidemiology, 2022, 56, 32-40.	1.1	2
598	Headaches in general medical practice. Terapevticheskii Arkhiv, 2022, 94, 141-121.	0.2	4
601	Headache and Eye Pain. , 2022, , 4693-4717.		0
602	Cranial autonomic symptoms in migraine: An observational study. Annals of Indian Academy of Neurology, 2022, 25, 654.	0.2	1
603	Evaluation of Paranasal Sinus Volumes and Anatomic Variations in Patients With Rhinogenic Headache. Harran Üniversitesi Tıp Fakültesi Dergisi, 0, , 215-220.	0.1	0
604	Glucose-Related Traits and Risk of Migraine—A Potential Mechanism and Treatment Consideration. Genes, 2022, 13, 730.	1.0	5
605	Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study. Headache, 2022, 62, 755-765.	1.8	5

ARTICLE IF CITATIONS Migraine in the workplace. ENeurologicalSci, 2022, 27, 100408. 607 0.5 14 608 Patient with migraine headaches., 0, , 297-306. The Impact of Migraine Disease on Work Productivity and Quality of Life Among the Adults in Riyadh, 609 0.2 1 Saudi Arabia. Cureus, 2022, , . Effectiveness of Acupuncture for Chronic Headache due to Perceived Stress. Awareness and Practices of Rabies and Animal Bite Management Among Victims Who Attended the OPD Services at Avissawella Base Hospital Sri Lanka, 0, , 72-80. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Clinical Neurology and Neurosurgery, 612 0.6 1 2022, 223, 107511. ANTIMIGRAINE ACTIVITY OF METHANOLIC EXTRACT OF ABROMA AUGUSTA L. IN LABORATORY ANIMALS. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 54-59. 0.3 The impact of migraine and probable migraine on productivity loss in Korea: A cross-sectional online 614 1.1 0 survey. PLoS ONE, 2022, 17, e0277905. Identification of genetic risk loci for depression and migraine comorbidity in Han Chinese residing in 1.3 Taiwan. Frontiers in Psychiatry, 0, 13, . Cross-Trait Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for 616 1.5 5 Multiple Sclerosis. Neurology, 2023, 100, . Predictors of treatmentâ€response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal antiâ€inflammatory drugs in acute treatment of episodic migraine. 1.8 Headache, 2023, 63, 342-352. Headache and Eye Pain., 2021, , 1-25. 618 0 Effect of temporal frequency on habituation in migraine. European Journal of Neuroscience, 2023, 57, 620 1.2 1383-1405. The variability of diagnosed migraine epidemiology amongst different municipalities in southern 621 2.5 0 Israel. Journal of Headache and Pain, 2023, 24, . Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine 2.5 cohort. Journal of Headache and Pain, 2023, 24, .